Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    granules-india-limited-m-2025-07-07

    Virtual Booth

    Contact Supplier

    Allsino Pharma excels in R&D & manufacturing of RSMs, GMP intermediates, & APIs; ISO-certified, GMP-compliant, accredited by NMPA.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Rhenium-186

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Plus Therapeutics' Reyobiq Shows Benefit in ReSPECT-LM Trial
    Plus Therapeutics' Reyobiq Shows Benefit in ReSPECT-LM Trial

    14 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/14/3081025/0/en/Plus-Therapeutics-REYOBIQ-Shows-Clinical-Benefit-and-Safety-in-the-ReSPECT-LM-Clinical-Trial-for-Patients-with-Leptomeningeal-Metastases-LM.html

    GLOBENEWSWIRE
    14 May 2025
    Share Share
    Plus Therapeutics Presents New Data on REYOBIQ in ReSPECT-LM Trial
    Plus Therapeutics Presents New Data on REYOBIQ in ReSPECT-LM Trial

    15 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/15/3061606/0/en/Plus-Therapeutics-Presents-New-Data-Highlighting-Clinical-Benefit-and-Safety-of-REYOBIQ-in-the-ReSPECT-LM-Clinical-Trial-for-Patients-with-Leptomeningeal-Metastases.html

    GLOBENEWSWIRE
    15 Apr 2025
    Share Share
    Plus Therapeutics Introduces Reyobiq as FDA-Accepted Name
    Plus Therapeutics Introduces Reyobiq as FDA-Accepted Name

    20 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/20/3046120/0/en/Plus-Therapeutics-Introduces-REYOBIQ-FDA-Accepted-Proprietary-Name-for-Lead-Drug-Candidate.html

    GLOBENEWSWIRE
    20 Mar 2025
    Share Share
    Plus Publishes Ph1 Rhenium-186 Data In Glioblastoma In Nature
    Plus Publishes Ph1 Rhenium-186 Data In Glioblastoma In Nature

    07 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/07/3038883/0/en/Plus-Therapeutics-Announces-Peer-Reviewed-Publication-in-Nature-Communications-Highlighting-Promising-Phase-1-Results-for-Rhenium-186Re-Obisbemeda-in-Glioblastoma.html

    GLOBENEWSWIRE
    07 Mar 2025
    Share Share
    Plus Therapeutics Gets FDA Orphan Drug Nod For Rhenium-186 In Lung Mets
    Plus Therapeutics Gets FDA Orphan Drug Nod For Rhenium-186 In Lung Mets

    06 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/06/3038083/0/en/Plus-Therapeutics-Granted-U-S-FDA-Orphan-Drug-Designation-for-Rhenium-186Re-Obisbemeda-for-the-Treatment-of-Leptomeningeal-Metastases-in-Patients-with-Lung-Cancer.html

    GLOBENEWSWIRE
    06 Mar 2025
    Share Share
    Plus Therapeutics to Present Data from ReSPECT-GBM Clinical Trial
    Plus Therapeutics to Present Data from ReSPECT-GBM Clinical Trial

    23 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/23/2502803/0/en/Plus-Therapeutics-to-Present-Data-from-ReSPECT-GBM-Clinical-Trial-at-the-European-Society-for-Medical-Oncology-Congress-2022.html

    GLOBENEWSWIRE
    23 Aug 2022
    Share Share